Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Crazy About Astex Pharmaceuticals, Inc. (ASTX)

Page 1 of 2

What’s a smart Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) investor to do?

In the 21st century investor’s toolkit, there are dozens of indicators shareholders can use to analyze publicly traded companies. Some of the most innovative are hedge fund and insider trading activity. At Insider Monkey, our research analyses have shown that, historically, those who follow the top picks of the top money managers can outperform their index-focused peers by a significant amount (see just how much).

Just as crucial, bullish insider trading activity is a second way to look at the marketplace. Obviously, there are a variety of reasons for an insider to sell shares of his or her company, but just one, very simple reason why they would behave bullishly. Plenty of academic studies have demonstrated the market-beating potential of this tactic if shareholders understand where to look (learn more here).

Now that that’s out of the way, let’s study the latest info for Astex Pharmaceuticals, Inc. (NASDAQ:ASTX).

What have hedge funds been doing with Astex Pharmaceuticals, Inc. (NASDAQ:ASTX)?

In preparation for the third quarter, a total of 17 of the hedge funds we track were bullish in this stock, a change of 6% from the first quarter. With hedgies’ sentiment swirling, there exists an “upper tier” of notable hedge fund managers who were boosting their stakes meaningfully.

Astex Pharmaceuticals, Inc. (NASDAQ:ASTX)According to our 13F database, OrbiMed Advisors, managed by Samuel Isaly, holds the biggest position in Astex Pharmaceuticals, Inc. (NASDAQ:ASTX). OrbiMed Advisors has a $13.4 million position in the stock, comprising 0.3% of its 13F portfolio. Sitting at the No. 2 spot is Joseph Edelman of Perceptive Advisors, with a $6.8 million position; the fund has 0.7% of its 13F portfolio invested in the stock. Remaining peers with similar optimism include Jim Simons’s Renaissance Technologies, Ken Griffin’s Citadel Investment Group and Israel Englander’s Millennium Management.

Consequently, specific money managers were leading the bulls’ herd. OrbiMed Advisors, managed by Samuel Isaly, initiated the most outsized position in Astex Pharmaceuticals, Inc. (NASDAQ:ASTX). OrbiMed Advisors had 13.4 million invested in the company at the end of the quarter. Joseph Edelman’s Perceptive Advisors also initiated a $6.8 million position during the quarter. The following funds were also among the new ASTX investors: Jim Simons’s Renaissance Technologies, Ken Griffin’s Citadel Investment Group, and Israel Englander’s Millennium Management.

What have insiders been doing with Astex Pharmaceuticals, Inc. (NASDAQ:ASTX)?

Legal insider trading, particularly when it’s bullish, is best served when the primary stock in question has experienced transactions within the past half-year. Over the latest six-month time frame, Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) has seen zero unique insiders buying, and zero insider sales (see the details of insider trades here).

We’ll also examine the relationship between both of these indicators in other stocks similar to Astex Pharmaceuticals, Inc. (NASDAQ:ASTX). These stocks are Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), Keryx Biopharmaceuticals (NASDAQ:KERX), Raptor Pharmaceutical Corp. (NASDAQ:RPTP), Endocyte, Inc. (NASDAQ:ECYT), and Kythera Biopharmaceuticals Inc (NASDAQ:KYTH). All of these stocks are in the drug manufacturers – major industry and their market caps are closest to ASTX’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!